Tocilizumab for acute exacerbation of rheumatic disease-associated interstitial lung disease: a real-world comparative cohort study
Abstract
BackgroundAcute exacerbation of rheumatic disease-associated interstitial lung disease (AE-RD-ILD) is life-threatening and is commonly managed with high-dose corticosteroids; however, no standardised evidence-based regimen has been established, particularly regarding adjunctive immunosuppressive therapy. We evaluated the effectiveness and safety of tocilizumab, an interleukin-6 receptor inhibitor, in hospitalised patients with AE-RD-ILD.MethodsIn this single-centre ambispective observational cohort study conducted between January 2023 and December 2024, patients treated with tocilizumab (n=26) were compared with controls receiving corticosteroid-based conventional immunosuppression without tocilizumab (n=36). The primary outcome was investigator-defined objective composite clinical response (CR) at 24 weeks. Secondary outcomes included glucocorticoid exposure, oxygen discontinuation, radiological change, new acute exacerbation (AE) events, death or lung transplantation, and safety.ResultsThe 24-week CR rate was higher with tocilizumab than in controls (80.8% [21/26] vs. 13.9% [5/36], p<0.001), with a risk ratio of 5.82 (95% CI 2.52-13.40) and an adjusted hazard ratio of 10.43 (95% CI 3.71-29.28); estimates were consistent in sensitivity analyses addressing competing risks, guarantee-time bias and additional confounders. Tocilizumab was associated with lower cumulative prednisone dose (3955 vs. 5005 mg, p=0.016), lower minimum maintenance dose (10.0 vs. 15.0 mg/day, p<0.001), more frequent oxygen discontinuation (76.9% vs. 30.6%, p<0.001), and greater CT-assessed reduction in ILD extent (20% vs. 15%, p=0.045). New AE events and death or lung transplantation were numerically less frequent but not statistically significant. At least one infection occurred in 23.1% of tocilizumab-treated patients and 38.9% of controls (p=0.272). During longer follow-up, seven controls subsequently switched to tocilizumab because of recurrent or progressive respiratory disease.ConclusionsTocilizumab was associated with higher short-term objective composite clinical response and improved respiratory and glucocorticoid-sparing outcomes in AE-RD-ILD. These findings support further evaluation of interleukin-6 receptor blockade in selected patients, while the non-randomised design and investigator-defined endpoint require cautious interpretation. Because the cohort was predominantly composed of patients with anti-synthetase-spectrum disease, the findings primarily apply to this phenotype and should not be extrapolated to RA-ILD, SSc-ILD or other RD-ILD subtypes without caution.
Related
- Clinical variables and quantitative CT radiomics for mortality risk stratification after acute exacerbation of idiopathic inflammatory myopathy-associated interstitial lung disease
- Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study
- ADAM8 is associated with asthma exacerbation by promoting lung macrophages apoptosis resistance through PI3K/AKT signaling pathway
- Correlative and Live-Cell Imaging of S100B-Promoter-Associated Interstitial Cells from the Cardiac Sinoatrial Node and Valves
- Serum SPP1 levels are associated with disease severity and 1-year mortality in primary Sjögren’s syndrome-associated interstitial lung disease
BibTeX
@article{xu2026tocilizumab,
title = {{Tocilizumab for acute exacerbation of rheumatic disease-associated interstitial lung disease: a real-world comparative cohort study}},
author = {Wenwen Xu and Yiyangzi Ma and Danting Zhang and Wanlong Wu and Shuhui Sun and Ruru Guo and Zhiwei Chen and Yakai Fu and Jie Chen and Kaiwen Wang and Xiaodong Wang and Yanwei Lin and Shuang Ye and Fang Du},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1985513},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1985513},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tocilizumab for acute exacerbation of rheumatic disease-associated interstitial lung disease: a real-world comparative cohort study
AU - Wenwen Xu
AU - Yiyangzi Ma
AU - Danting Zhang
AU - Wanlong Wu
AU - Shuhui Sun
AU - Ruru Guo
AU - Zhiwei Chen
AU - Yakai Fu
AU - Jie Chen
AU - Kaiwen Wang
AU - Xiaodong Wang
AU - Yanwei Lin
AU - Shuang Ye
AU - Fang Du
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1985513
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1985513
AB - BackgroundAcute exacerbation of rheumatic disease-associated interstitial lung disease (AE-RD-ILD) is life-threatening and is commonly managed with high-dose corticosteroids; however, no standardised evidence-based regimen has been established, particularly regarding adjunctive immunosuppressive therapy. We evaluated the effectiveness and safety of tocilizumab, an interleukin-6 receptor inhibitor, in hospitalised patients with AE-RD-ILD.MethodsIn this single-centre ambispective observational cohort study conducted between January 2023 and December 2024, patients treated with tocilizumab (n=26) were compared with controls receiving corticosteroid-based conventional immunosuppression without tocilizumab (n=36). The primary outcome was investigator-defined objective composite clinical response (CR) at 24 weeks. Secondary outcomes included glucocorticoid exposure, oxygen discontinuation, radiological change, new acute exacerbation (AE) events, death or lung transplantation, and safety.ResultsThe 24-week CR rate was higher with tocilizumab than in controls (80.8% [21/26] vs. 13.9% [5/36], p<0.001), with a risk ratio of 5.82 (95% CI 2.52-13.40) and an adjusted hazard ratio of 10.43 (95% CI 3.71-29.28); estimates were consistent in sensitivity analyses addressing competing risks, guarantee-time bias and additional confounders. Tocilizumab was associated with lower cumulative prednisone dose (3955 vs. 5005 mg, p=0.016), lower minimum maintenance dose (10.0 vs. 15.0 mg/day, p<0.001), more frequent oxygen discontinuation (76.9% vs. 30.6%, p<0.001), and greater CT-assessed reduction in ILD extent (20% vs. 15%, p=0.045). New AE events and death or lung transplantation were numerically less frequent but not statistically significant. At least one infection occurred in 23.1% of tocilizumab-treated patients and 38.9% of controls (p=0.272). During longer follow-up, seven controls subsequently switched to tocilizumab because of recurrent or progressive respiratory disease.ConclusionsTocilizumab was associated with higher short-term objective composite clinical response and improved respiratory and glucocorticoid-sparing outcomes in AE-RD-ILD. These findings support further evaluation of interleukin-6 receptor blockade in selected patients, while the non-randomised design and investigator-defined endpoint require cautious interpretation. Because the cohort was predominantly composed of patients with anti-synthetase-spectrum disease, the findings primarily apply to this phenotype and should not be extrapolated to RA-ILD, SSc-ILD or other RD-ILD subtypes without caution.
SN - 1664-3224
ER -